WO2014111956A3 - Sustained release formulations of curcuminoids and method of preparation thereof - Google Patents

Sustained release formulations of curcuminoids and method of preparation thereof Download PDF

Info

Publication number
WO2014111956A3
WO2014111956A3 PCT/IN2014/000031 IN2014000031W WO2014111956A3 WO 2014111956 A3 WO2014111956 A3 WO 2014111956A3 IN 2014000031 W IN2014000031 W IN 2014000031W WO 2014111956 A3 WO2014111956 A3 WO 2014111956A3
Authority
WO
WIPO (PCT)
Prior art keywords
sustained
release
curcuminoid
curcuminoids
sustained release
Prior art date
Application number
PCT/IN2014/000031
Other languages
French (fr)
Other versions
WO2014111956A2 (en
Inventor
Benny Antony
Original Assignee
Benny Antony
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Benny Antony filed Critical Benny Antony
Publication of WO2014111956A2 publication Critical patent/WO2014111956A2/en
Publication of WO2014111956A3 publication Critical patent/WO2014111956A3/en
Priority to US14/800,950 priority Critical patent/US10286027B2/en
Priority to US15/478,013 priority patent/US20170202785A1/en
Priority to US16/171,117 priority patent/US20190060253A1/en
Priority to US17/002,568 priority patent/US12053438B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

A sustained curcuminoid release pharmaceutical composition is provided. The sustained curcuminoid release composition includes bioavailable curcumin formulation and release rate controlling excipients such as ethyl cellulose, shellac, copolymer of ethyl acrylate and methyl methacrylate, acrylic acid copolymers, hydroxy propyl methyl cellulose (HPMC), hydroxy propyl cellulose. A process for the manufacturing of sustained release curcuminoid formulations is provided.
PCT/IN2014/000031 2005-05-30 2014-01-16 Sustained release formulations of curcuminoids and method of preparation thereof WO2014111956A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US14/800,950 US10286027B2 (en) 2005-05-30 2015-07-16 Sustained release formulations of curcuminoids and method of preparation thereof
US15/478,013 US20170202785A1 (en) 2005-05-30 2017-04-03 Formulation of Curcumin with Enhanced Bioavailability of Curcumin and method of preparation and treatment thereof
US16/171,117 US20190060253A1 (en) 2005-05-30 2018-10-25 Formulation of Curcumin with Enhanced Bioavailability of Curcumin and method of preparation and treatment thereof
US17/002,568 US12053438B2 (en) 2005-05-30 2020-08-25 Formulation of curcuminoids with enhanced bioavailability of curcumin, demethoxycurcumin, bisdemethoxycurcumin and method of preparation and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN226/CHE/2013 2013-01-17
IN226CH2013 IN2013CH00226A (en) 2013-01-17 2013-01-17

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
US14/094,725 Division US8895087B2 (en) 2005-05-30 2013-12-02 Composition to enhance the bioavailability of curcumin
US14/698,944 Continuation-In-Part US10543277B2 (en) 2005-05-30 2015-04-29 Formulation of curcumin with enhanced bioavailability of curcumin and method of preparation and treatment thereof

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US14/094,725 Continuation US8895087B2 (en) 2005-05-30 2013-12-02 Composition to enhance the bioavailability of curcumin
US14/206,044 Continuation US9492402B2 (en) 2005-05-30 2014-03-12 Formulation of curcuminoids with enhanced bioavailability of curcumin, demethoxycurcumin, bisdemethoxycurcumin and method of preparation and uses thereof
US14/800,950 Continuation US10286027B2 (en) 2005-05-30 2015-07-16 Sustained release formulations of curcuminoids and method of preparation thereof

Publications (2)

Publication Number Publication Date
WO2014111956A2 WO2014111956A2 (en) 2014-07-24
WO2014111956A3 true WO2014111956A3 (en) 2014-12-04

Family

ID=51210161

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2014/000031 WO2014111956A2 (en) 2005-05-30 2014-01-16 Sustained release formulations of curcuminoids and method of preparation thereof

Country Status (2)

Country Link
IN (1) IN2013CH00226A (en)
WO (1) WO2014111956A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10363225B2 (en) * 2016-08-11 2019-07-30 Akay Flavours & Aromatics Pvt, Ltd Non-bleeding bioactive natural pigments which prevent color and dust explosions, method of preparation thereof
EP3870201A4 (en) * 2018-10-23 2022-08-03 Stabicon Life Sciences Pvt. Ltd. Formulation comprising water soluble particles of a non-curcuminoid and a curcuminoid
EP3982990A4 (en) * 2019-06-11 2023-06-21 Olene Life Sciences Private Limited Bioavailable turmeric composition and process for preparation thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007146234A2 (en) * 2006-06-09 2007-12-21 Merrion Research Ii Limited Solid oral dosage form containing an enhancer
WO2011082290A2 (en) * 2009-12-31 2011-07-07 Organomed Corporation Formulations from natural products, turmeric, and aspirin
WO2011125070A2 (en) * 2010-04-05 2011-10-13 Benny Antony Formulation of curcumin with enhanced bioavailability of curcumin and method of preparation and treatment thereof
WO2012023146A1 (en) * 2010-08-16 2012-02-23 Benny Antony A pharmaceutical composition of reformulated turmeric extract and a method thereof
WO2012116238A1 (en) * 2011-02-23 2012-08-30 Dispersol Technologies, Llc PHARMACEUTICAL FORMULATIONS OF ACETYL-11-KETO-β-BOSWELLIC ACID, DIINDOLYLMETHANE, AND CURCUMIN FOR PHARMACEUTICAL APPLICATIONS

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007146234A2 (en) * 2006-06-09 2007-12-21 Merrion Research Ii Limited Solid oral dosage form containing an enhancer
WO2011082290A2 (en) * 2009-12-31 2011-07-07 Organomed Corporation Formulations from natural products, turmeric, and aspirin
WO2011125070A2 (en) * 2010-04-05 2011-10-13 Benny Antony Formulation of curcumin with enhanced bioavailability of curcumin and method of preparation and treatment thereof
WO2012023146A1 (en) * 2010-08-16 2012-02-23 Benny Antony A pharmaceutical composition of reformulated turmeric extract and a method thereof
WO2012116238A1 (en) * 2011-02-23 2012-08-30 Dispersol Technologies, Llc PHARMACEUTICAL FORMULATIONS OF ACETYL-11-KETO-β-BOSWELLIC ACID, DIINDOLYLMETHANE, AND CURCUMIN FOR PHARMACEUTICAL APPLICATIONS

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
ANTONY B ET AL.: "A pilot cross-over study to evaluate human oral bioavailability of BCM-95® CG (BiocurcumaxTM), a novel bioenhanced preparation of curcumin", INDIAN J PHARM SCI, vol. 70, 2008, pages 445 - 449 *
DATABASE TKDL "Haridr", accession no. G/3529 *
DATABASE TKDL "Haridra Arka Gunah", accession no. K14/51B *
DATABASE TKDL "Haridra Guna Karma", accession no. J/245A *
DATABASE TKDL "Haridrgu'a", accession no. S/3120 *
DATABASE TKDL "Kulirntha Patchai Kaaram", accession no. R 01/17 *
DATABASE TKDL "Nisa Guna", accession no. G9/70 *
MINPEI KURODA ET AL.: "Hypoglycemic effects of turmeric (Curcuma longa L. Rhizomes) on genetically diabetic KK-Ay mice.", BIOL PHARM BULL, vol. 28, no. 5, 2005, pages 937 - 939 *

Also Published As

Publication number Publication date
WO2014111956A2 (en) 2014-07-24
IN2013CH00226A (en) 2015-08-07

Similar Documents

Publication Publication Date Title
EP3260463A4 (en) Deuterated chenodeoxycholic acid derivative and pharmaceutical composition comprising compound thereof
IL252324B (en) A solid dispersion comprising arn-509 and a poly(meth)acrylate copolymer, particles and pharmaceutical formulation comprising the same, methods of their preparation and uses thereof
WO2014170755A3 (en) Sustained-release formulations of colchicine and methods of using same
MY190392A (en) A delayed release drug formulation
WO2017037594A3 (en) Pharmaceutical composition used for reducing localised fat and use of pharmaceutical composition
EP3054929A4 (en) Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
WO2014204881A8 (en) Delayed release cysteamine bead formulation
PH12015502556A1 (en) Modified release formulation
CA2863376A1 (en) Gastroretentive tablets
WO2014207664A3 (en) Stable pharmaceutical composition of asenapine
EP3102585A4 (en) Boronic acid esters and pharmaceutical formulations thereof
BR112017009510A2 (en) compositions comprising cyclosporine
IL262163A (en) Delayed release pharmaceutical formulations comprising valproic acid, and uses thereof
WO2014111956A3 (en) Sustained release formulations of curcuminoids and method of preparation thereof
PE20100471A1 (en) SILDENAFIL PULSATILE RELEASE COMPOSITION AND PROCESS TO PREPARE IT
WO2012074830A3 (en) Modified release tranexamic acid formulation
CA2863371A1 (en) Pregabalin gr tablets
EP3352739A4 (en) Lipoic acid choline ester compositions and methods to generate biocompatible ophthalmic formulations
WO2012147101A3 (en) Pharmaceutical compositions of raltegravir, methods of preparation and use thereof
EP3167893A4 (en) Pharmaceutical composition containing spirulina maxima extract as active ingredient for preventing and treating retinal diseases
EP3522889A4 (en) Delayed release pharmaceutical composition of pantoprazole and process for preparation thereof
EP3485877A4 (en) Oral pharmaceutical preparation having improved content uniformity, containing tamsulosin hydrochloride-containing extended release pellet
GEP201706743B (en) Oral formulation for the treatment of cardiovascular diseases
EP3434665A4 (en) Method for producing -fluoro acrylic acid ester, and composition containing highly-pure fluorocyclopropane derivative, and composition containing highly-pure -fluoro acrylic acid ester
EP2452678A3 (en) Pulsatile-release pharmaceutical formulation of dexlansoprazole

Legal Events

Date Code Title Description
122 Ep: pct application non-entry in european phase

Ref document number: 14740317

Country of ref document: EP

Kind code of ref document: A2